Table 3 Clinical outcome and impact on oncological treatment
Outcome | n (out of 178) | Percentage |
|---|---|---|
Hospital admission | 125 | 70.2% |
Clinical worsening | 47 | 26.4% |
Admission to ICU | 16 | 9.0% |
At data cutoff | ||
Death | 31 | 17.4% |
Primary cause of death: COVID-19 | 20 | |
Primary cause of death: cancer | 11 | |
Never hospitalized | 51 | 28.7% |
Still hospitalized | 16 | 9.0% |
Discharged | 80 | 44.9% |
Impact of COVID-19 on cancer treatment | ||
No change in strategy | ||
No delay in ongoing treatment | 51 | 28.8% |
Delay in ongoing treatment | 73 | 41.2% |
Change in strategy | ||
Dose modification | 2 | 1.1% |
Change of treatment modality | 6 | 3.4% |
Change of systemic therapy | 7 | 4.0% |
End of treatment (surveillance) | 7 | 4.0% |
End of treatment (palliative care or death) | 31 | 17.5% |
NA | 1 | |
